论文部分内容阅读
用促黄体激素释放激素(LHRH)同类物治疗晚期的前列腺癌,其效果已为临床研究证明,没有发现明显的毒性作用。但是,本文报告两例用D-Trp~6-LHRH同类物治疗,突然发生严重的异常情况。 例一 一例70岁的前列腺癌患者,1981年曾用己烯雌酚(diethylstilboestrol)治疗,每日3mg,治疗3个月。1984年1月,这位患者因胸部和腰部轻微疼痛而住院。经X线检查发现有骨、肺转移。超声波探测仪检查发现主动脉旁淋巴结亦有转移。该病人接受了D-Trp~6-LHRH的治疗(每日皮下注射500μg),预计治疗7天,第8天改用长效的上述同类物制剂(皮下注射100μg)。治疗的第4天,病人突然出现严重情况:剧烈疼痛,要求麻醉性止痛剂;肝肿大,但超
The use of luteinizing hormone-releasing hormone (LHRH) analogues for the treatment of advanced prostate cancer has been proven by clinical studies and no significant toxic effects have been found. However, this article reports two cases of treatment with D-Trp~6-LHRH congener, sudden severe abnormalities. Example 1 A 70-year-old prostate cancer patient was treated with diethylstilboestrol in 1981, 3 mg daily for 3 months. In January 1984, the patient was hospitalized because of slight pain in the chest and waist. X-ray examination revealed bone and lung metastases. Ultrasound detectors revealed metastases in the paraaortic lymph nodes. The patient received treatment with D-Trp~6-LHRH (subcutaneous injection of 500 [mu]g daily) and is expected to be treated for 7 days. On the 8th day, the long-acting congener preparation of the same kind was used (subcutaneous injection of 100 [mu]g). On the fourth day of treatment, the patient suddenly had a severe condition: severe pain, requiring anesthetic analgesics; hepatomegaly, but super